BR112018012707A2 - inibidores da interação de menin-mll - Google Patents

inibidores da interação de menin-mll

Info

Publication number
BR112018012707A2
BR112018012707A2 BR112018012707A BR112018012707A BR112018012707A2 BR 112018012707 A2 BR112018012707 A2 BR 112018012707A2 BR 112018012707 A BR112018012707 A BR 112018012707A BR 112018012707 A BR112018012707 A BR 112018012707A BR 112018012707 A2 BR112018012707 A2 BR 112018012707A2
Authority
BR
Brazil
Prior art keywords
menin
interaction inhibitors
mll interaction
inhibitors
interaction
Prior art date
Application number
BR112018012707A
Other languages
English (en)
Inventor
Dong Chengguo
A Claremon David
Yuan Jing
Jia Lanqi
Zhuang Linghang
Venkatraman Shankar
B Singh Suresh
Zheng Yajun
Fan Yi
Original Assignee
Vitae Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitae Pharmaceuticals Inc filed Critical Vitae Pharmaceuticals Inc
Publication of BR112018012707A2 publication Critical patent/BR112018012707A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a inibidores da interação de menin com mll e proteínas de fusão de mll, composições farmacêuticas contendo os mesmos, e seu uso no tratamento de câncer e outras doenças mediadas pela interação de menin-mll.
BR112018012707A 2015-12-22 2016-12-21 inibidores da interação de menin-mll BR112018012707A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562270973P 2015-12-22 2015-12-22
PCT/US2016/068016 WO2017112768A1 (en) 2015-12-22 2016-12-21 Inhibitors of the menin-mll interaction

Publications (1)

Publication Number Publication Date
BR112018012707A2 true BR112018012707A2 (pt) 2019-01-29

Family

ID=57758822

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018012707A BR112018012707A2 (pt) 2015-12-22 2016-12-21 inibidores da interação de menin-mll

Country Status (12)

Country Link
US (1) US20190010167A1 (pt)
EP (1) EP3394064A1 (pt)
JP (1) JP2018538330A (pt)
KR (1) KR20180103053A (pt)
CN (1) CN108779116A (pt)
AU (1) AU2016378579A1 (pt)
BR (1) BR112018012707A2 (pt)
CA (1) CA3005945A1 (pt)
IL (1) IL259560A (pt)
MX (1) MX2018007703A (pt)
RU (1) RU2018126774A (pt)
WO (1) WO2017112768A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015007061B1 (pt) * 2012-09-28 2022-10-04 Cancer Research Technology Limited Composto, composição farmacêutica e uso do composto
US10246464B2 (en) 2014-09-09 2019-04-02 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
EP3302057A4 (en) 2015-06-04 2018-11-21 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
EP3429591B1 (en) 2016-03-16 2023-03-15 Kura Oncology, Inc. Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
BR112018068702A2 (pt) 2016-03-16 2019-01-15 Kura Oncology Inc inibidores bicíclicos em ponte de menin-mll e métodos de uso
JP6991585B2 (ja) 2016-05-02 2022-01-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン メニン阻害剤としてのピペリジン
BR122024002146A2 (pt) * 2016-06-10 2024-03-05 Vitae Pharmaceuticals, Inc. Compostos inibidores da interação de menina-llm e forma cristalina destes
WO2018024602A1 (en) * 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
US20220227786A1 (en) * 2016-09-14 2022-07-21 Janssen Pharmaceutica Nv Spiro Bicyclic Inhibitors Of Menin-MLL Interaction
US10611778B2 (en) 2016-09-14 2020-04-07 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-MLL interaction
AU2017326487B2 (en) 2016-09-14 2021-08-05 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CA3044739A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction
EA201991448A1 (ru) 2017-01-06 2019-12-30 Янссен Фармацевтика Нв Азепановые ингибиторы взаимодействия менин-mll
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
SG11201909083UA (en) 2017-03-31 2019-10-30 Univ Michigan Regents Piperidines as covalent menin inhibitors
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TW201920170A (zh) * 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
WO2019120209A1 (en) * 2017-12-20 2019-06-27 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-mll interaction
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN112105621B (zh) * 2018-03-30 2024-02-20 住友制药株式会社 光学活性桥型环状仲胺衍生物
EP3553061A1 (en) * 2018-04-12 2019-10-16 Centre National De La Recherche Scientifique (Cnrs) New inhibitors of bone resorption
WO2020032105A1 (ja) 2018-08-08 2020-02-13 大日本住友製薬株式会社 光学活性な架橋型ピペリジン誘導体
US10815241B2 (en) 2018-08-27 2020-10-27 Sumitomo Dainippon Pharma Co., Ltd. Optically active azabicyclo ring derivative
BR112021002090A8 (pt) * 2018-08-27 2022-12-06 Sumitomo Dainippon Pharma Co Ltd Derivado azabicíclico opticamente ativo
EP3858813A4 (en) * 2018-09-27 2022-06-22 Shenzhen Chipscreen Biosciences Co., Ltd. QUINOLONE DERIVATIVE WITH INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY
CN113874015A (zh) 2018-12-21 2021-12-31 细胞基因公司 Ripk2的噻吩并吡啶抑制剂
US20220380365A1 (en) * 2019-09-27 2022-12-01 Sumitomo Dainippon Pharma Co., Ltd. Crosslinked optically active secondary amine derivative
TW202138367A (zh) * 2019-12-19 2021-10-16 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
CN114478568A (zh) * 2020-10-27 2022-05-13 苏州优理生物医药科技有限公司 一种噻吩并嘧啶类化合物、包含其药物组合物及其应用
CA3215379A1 (en) 2021-05-08 2022-11-17 Olivier Alexis Georges Querolle Substituted spiro derivatives
CN117730081A (zh) 2021-05-08 2024-03-19 詹森药业有限公司 取代的螺环衍生物
PE20240593A1 (es) * 2021-05-11 2024-03-21 Janssen Pharmaceutica Nv Terapias de combinacion
KR20240047338A (ko) 2021-05-14 2024-04-12 신닥스 파마슈티컬스, 인크. 메닌-mll 상호작용의 억제제
EP4347588A1 (en) 2021-06-01 2024-04-10 JANSSEN Pharmaceutica NV Substituted phenyl-1h-pyrrolo[2, 3-c]pyridine derivatives
CN117425659A (zh) 2021-06-03 2024-01-19 詹森药业有限公司 哒嗪或被螺环胺取代的1,2,4-三嗪
WO2022262796A1 (en) * 2021-06-17 2022-12-22 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-m ethylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
CN116903609A (zh) * 2021-11-05 2023-10-20 上海优理惠生医药有限公司 一种化合物、包含其的药物组合物及其应用
TW202333690A (zh) * 2021-12-03 2023-09-01 大陸商燁輝醫藥科技（上海）有限公司 羰基取代的二氮雜螺化合物及其用途
TW202337435A (zh) * 2021-12-09 2023-10-01 美商巴拉療法公司 梅嫩蛋白（ｍｅｎｉｎ）－ＭＬＬ相互作用之抑制劑
WO2023107687A1 (en) * 2021-12-09 2023-06-15 Bala Therapeutics, Inc. Inhibitors of menin-mll interaction
WO2024033479A1 (en) * 2022-08-11 2024-02-15 Remynd N.V. (aza)spiroheptane derivatives for the treatment of neurodegenerative disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2009001152A1 (es) * 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
TW201038572A (en) * 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
WO2011032050A2 (en) * 2009-09-11 2011-03-17 Trius Therapeutics, Inc. Gyrase inhibitors
WO2012016082A1 (en) * 2010-07-30 2012-02-02 Oncotherapy Science, Inc. Quinoline derivatives and melk inhibitors containing the same
US20140243239A1 (en) * 2011-10-12 2014-08-28 University Of North Carolina At Chapel Hill Multiplexed kinase inhibitor beads and uses thereof
KR20150128768A (ko) * 2013-03-07 2015-11-18 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 티에노[3,2-d]피리미딘-6-카르복스아미드 및 유사체
WO2014145512A2 (en) * 2013-03-15 2014-09-18 President And Fellows Of Harvard College Potent small molecule inhibitors of autophagy, and methods of use thereof
CN105732636B (zh) * 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用

Also Published As

Publication number Publication date
JP2018538330A (ja) 2018-12-27
IL259560A (en) 2018-07-31
US20190010167A1 (en) 2019-01-10
CN108779116A (zh) 2018-11-09
CA3005945A1 (en) 2017-06-29
AU2016378579A1 (en) 2018-06-14
WO2017112768A1 (en) 2017-06-29
MX2018007703A (es) 2018-11-09
KR20180103053A (ko) 2018-09-18
EP3394064A1 (en) 2018-10-31
RU2018126774A (ru) 2020-01-23

Similar Documents

Publication Publication Date Title
BR112018012707A2 (pt) inibidores da interação de menin-mll
BR112019005030A2 (pt) inibidores da interação de menina-llm
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
BR112017012344A2 (pt) anticorpos anti-c10orf54 e usos dos mesmos
BR112017012342A2 (pt) compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos
BR112017017727A8 (pt) Heterociclos bicíclicos como inibidores de fgfr4
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
BR112016023948A2 (pt) proteínas fc multiméricas
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
BR112017001796A2 (pt) composições de flagelina e seus usos
BR112018012262A2 (pt) composições de interleucina-15 e seus usos
EA201690159A1 (ru) Способы и композиции для лечения рака
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
BR112017028331A2 (pt) proteínas de fusão que se ligam a receptores fc humanos
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
AR101486A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
BR112017016333A2 (pt) compostos anticâncer
BR112016012002A2 (pt) Vitanolídeos úteis para o tratamento de doenças neurodegenerativas
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
BR112017012608A2 (pt) composto, composição farmacêutica e uso de um composto
CL2018002848A1 (es) Formulaciones liquidas de fosfoplatino
PH12017501979A1 (en) Pharmaceutical compound

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]